Key AstraZeneca drug shown to reduce risk of death from lung cancer

LONDON (Reuters) - AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday.